Non‐small cell lung cancer (NSCLC) accounts for 85% of lung cancer patients.1, 2 Treatment of NSCLC includes surgery, radiotherapy, chemotherapy, immunotherapy (monoclonal antibodies against programmed cell death 1, programmed cell death 1 ligand 1 or cytotoxic T‐lymphocyte associated protein 4) and molecularly targeted therapies (kinases inhibitors of epidermal growth factor receptor, anaplastic lymphoma receptor tyrosine kinase, ROS proto‐oncogene 1, receptor tyrosine kinase or B‐Raf proto‐oncogene, serine/threonine kinase and mitogen‐activated protein kinase kinase 1). This evidence concerns the gene ALK and non-small cell lung carcinoma.